NIM : 61608100821064
Referensi
1. Viollet, B. et. al., 2012. “Cellular and molecular mechanisms of metfromin: an
overview”. J. Clin. Sci., London
2. Luna, B. & Mark N. F., 2001. “Oral Agents in the Management of Type 2
Diabetes Mellitus”. Am. Fam. Physician, USA
3. He, Ling & Fredric E.W., 2015. “Metformin Action : Concentrations Matter”.
Cell Metabolism, USA
4. Nguyen, L., et. al., 2018. “Metformin from mother to unborn child - Are there
unwarranted effects ?”. Elsevier, Singapore
5. Lorena, I. et. al., 2022. ”Polycystic Ovarian Disease”. StatPearls Publishing,
USA
6. Palomba, S. et. al., 2010. “Systemic and local effects of metformin
administration in patients with polycystic ovary syndrome (PCOS) : relationship
to the ovulatory response”. Hum. Reprod. 25(4)
7. Lebinger, T. G., 2007. “Metformin and Polycystic Ovary Syndrome”. Curr.
Opin. Endocrinol. Diabetes Obes. (1) 14:132-40